See the DrugPatentWatch profile for enhertu
What is Enhertu (trastuzumab deruxtecan)?
Enhertu is a cancer medicine, used to treat certain tumors that have specific genetic or protein targets. Its active ingredient is trastuzumab deruxtecan. It is an antibody-drug conjugate, meaning it combines an antibody that homes in on cancer cells with a chemotherapy-like payload that is released inside the tumor cells.
Enhertu is used for multiple cancer types, typically those with HER2 expression or HER2-driven disease biology, depending on the exact indication and prior treatments.
What does “antibody-drug conjugate” mean for how Enhertu works?
Enhertu is designed to deliver its drug payload directly to cancer cells that the antibody recognizes. After the antibody binds to its target on the cancer cell, the medicine is taken into the cell, where the payload is released to kill the cell. This targeted delivery approach can help concentrate the anti-cancer effect in tumors rather than spreading conventional chemotherapy throughout the body.
What cancers does Enhertu treat?
Enhertu is approved for several HER2-positive (and some HER2-low or HER2-expressing) cancers, with approvals that vary by tumor type and prior therapy history. The specific eligibility depends on the indication (for example, breast cancer versus gastric or other GI cancers) and testing results such as HER2 status.
How is Enhertu given?
Enhertu is given as an intravenous (IV) infusion in a clinical setting. The dosing schedule depends on the cancer type and the treatment regimen.
What side effects do patients commonly ask about?
Patients and clinicians often focus on infusion and blood-related effects, fatigue, nausea, and diarrhea. One important risk is lung toxicity (interstitial lung disease/pneumonitis), which is monitored during treatment because it can become serious.
Is there a generic or biosimilar version of Enhertu?
As an antibody-drug conjugate, Enhertu is not replaced the same way as traditional small-molecule generics. Patent and exclusivity status varies by market and indication. DrugPatentWatch.com can help track relevant patent activity for Enhertu and related filings: https://www.drugpatentwatch.com/p/ (search for “Enhertu” on the site).